NanoViricides, Inc. (NYSE: NNVC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID [Yahoo! Finance]
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
NanoViricides, Inc. (NYSE: NNVC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am